Discovering, developing and delivering
For more than 100 years, we have been translating the unmet medical needs of people living with a serious chronic disease into innovative medicines and delivery systems.
Our treatments today are helping millions of people living with diabetes, obesity, rare bleeding disorders and growth hormone-related disorders.
From our labs to our factory floors, we are discovering and developing innovative biological medicines and making them accessible to patients throughout the world.
More than 20 medicines helping patients across four therapeutic areas
Approximately 860 people working in R&D in the U.S.
More than 1,000,000 patients helped to afford our medicines through NovoCare.com
We focus on serious chronic diseases affecting millions of Americans who are among our world’s most urgent health challenges.
By combining our innovation and commercial excellence, we draw upon insights from patients and partners to transform bold ideas into life-saving medicines.
We make long-term investments in novel treatments and technologies, to continually advance the development of medical devices and digital health solutions and making them accessible for the people who depend on them.
When someone living with a chronic disease is not cared for properly, or left untreated altogether, they are at risk of developing life-threatening complications.
Vulnerable and low-income communities are often hit the hardest. The cost and access to medical care can place a devastating burden on individuals, their families and even whole societies.
Affordability is a major issue and a complicated one. There are lots of question marks and many are looking to us for answers. What we do know for sure is that more needs to be done across the healthcare system for patients. And we will be a part of that.
Defeating diabetes and other serious chronic diseases including obesity is not something we can do alone.
In our research, development, manufacturing and commercial operations, we work with partners who complement our own expertise.
We are always on the lookout for new opportunities with people and organizations who are interested in collaborating to change patients’ lives, together.
Sometimes the best path to discovery is through open collaboration. We strongly believe in this.
From our innovation challenges to the sharing of our molecular compounds for preclinical research, we aim to create new innovation ecosystems that accelerate new medicine discovery and better digital health solutions.
